New drug combo targets tough cancers in early trial
Disease control
Recruiting now
This early-stage study tests a new oral drug, FX-909, alone or with another drug (pembrolizumab) in people with advanced solid tumors, including a type of bladder cancer. The main goals are to check safety and find the best dose. About 120 adults will take part, taking daily pill…
Phase: PHASE1 • Sponsor: Flare Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC